Fig. 3.
Treatment with RD2 significantly reduced oligomeric Aβ species. Oligomeric Aβ levels in the fractions of density gradient ultracentrifuged brain homogenates of RD2- and placebo-treated APP/PS1 mice were analyzed by the aggregate-specific and highly sensitive sFIDA assay. Results revealed a significant decrease in oligomeric Aβ species in fraction 10 of RD2- compared to placebo-treated mice. sFIDA readout was converted to Aβ oligomer concentrations after calibration with Aβ1–42-SiNaP (internal standard calibration) (silica nanoparticles). Data is represented as mean ± SEM. Placebo n = 4, RD2 n = 5. **p < 0.01